logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Immunovant Inc: Positive IMVT-1402 Results that Would Confirm Best-in-Class Potential in Treating Autoimmune Diseases

Immunovant Inc in the NEWS Immunovant, Inc. ( IMVT ) announced initial data from 600 mg MAD cohort of a Phase 1 clinical trial of its product IMVT-1402 in healthy adults. The Phase 1 clinical trial is a randomized, double-blind,...

Read More

November 28, 2023

0

Carlisle Companies Inc and Arcturus Therapeutics Granted Approval in Japan of a Novel Self-Amplifying mRNA Vaccine for COVID-19  

Carlisle Companies Inc and Arcturus Therapeutics in the NEWS Today, November 28, 2023, Global biotechnology leaders Carlisle Companies Inc ( CSL )  and Arcturus Therapeutics ( ARCT ) announced that Japan's Ministry of Health, Labor and Welfare ( MHLW ) granted...

Read More

November 28, 2023

0

AbbVie Inc to Acquire ImmunoGen

AbbVie Inc Acquisition of Immunogen in the News AbbVie Inc. ( ABBV ) and ImmunoGen ( IMGN ) today announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE® (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug...

Read More

November 30, 2023

0

Why Virpax Pharmaceuticals Stock Soared on Two Consecutive Days

Virpax Pharmaceuticals  Virpax Pharmaceuticals ( VRPX ) - a company specializing in developing product candidates for pain management, CNS and anti-viral indications, announced the receipt of a written pre-investigational new drug ( pre-IND ) response from the U.S. Food and Drug...

Read More

August 18, 2021

0

Axsome Therapeutics: Treating Major Depressive Disorder. Vivos Therapeutics: Improving the Treatment of Obstructive Sleep Apnea

Axsome Therapeutics Inc and Major Depressive Disorder In a teleconference on August 20, 2021, the U.S. Food and Drug Administration ( FDA ) informed Axsome Therapeutics ( AXSM ) that its review of the new drug application ( NDA )...

Read More

August 23, 2021

0

Cassava Sciences Issued a Response to Claims Posted After Market Yesterday. See Also: Cassava Sciences Good News

Cassava Sciences Responds to Misleading Posts Cassava Sciences ( SAVA ) today issued a response to claims that were posted online yesterday after market hours. Cassava Sciences believes the claims made in this post regarding scientific integrity are false and...

Read More

August 25, 2021

0

EyePoint Pharmaceuticals: Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD

EyePoint Pharmaceuticals Treating Wet Age-Related Macular Degeneration In today's press release , EyePoint Pharmaceuticals ( EYPT ) announced positive topline results of its Phase 2 DAVIO 2 trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet age-related macular...

Read More

December 4, 2023

0

Why Syndax and Incyte Traded UP in Today’s Early Morning  

Syndax Pharmaceuticals and Incyte Syndax Pharmaceuticals ( SNDX ) and Incyte ( INCY ) announced positive data from the pivotal AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in adult and pediatric patients with chronic graft-versus-host disease ( GVHD ) following...

Read More

July 24, 2023

0

Roche Announces Positive Phase III Results for Inavolisib Combination in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation

Roche in the NEWS From Basel, today, December 5, 2023 - Roche ( RHHBY ) announced positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib ( Ibrance® ) and fulvestrant as a...

Read More

December 5, 2023

0

Merck and Moderna Initiated Phase 3 Study Evaluating V940 in Combination with KEYTRUDA® for Patients with Resected High-Risk Melanoma

Merck and Moderna Inc Announcement Merck ( MRK ) and Moderna Inc ( MRNA )  announced the initiation of the pivotal Phase 3 randomized V940-001clinical trial evaluating V940 ( mRNA- 4157 ), an investigational individualized neoantigen therapy ( INT ),...

Read More

July 26, 2023

0

  • Previous
  • 1
  • 2
  • ...
  • 145
  • 146
  • 147
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy